The latest price target for Lipocine (NASDAQ:LPCN) was reported by HC Wainwright & Co. on April 6, 2026. The analyst firm set a price target for $0.00 expecting LPCN to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Lipocine (NASDAQ:LPCN) was provided by HC Wainwright & Co., and Lipocine downgraded their neutral rating.

There is no last upgrade for Lipocine

The last downgrade for Lipocine Inc happened on April 6, 2026 when HC Wainwright & Co. changed their price target from N/A to N/A for Lipocine Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lipocine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lipocine was filed on April 6, 2026 so you should expect the next rating to be made available sometime around April 6, 2027.

While ratings are subjective and will change, the latest Lipocine (LPCN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Lipocine (LPCN) is trading at is $2.51, which is out of the analyst’s predicted range.